ClinicalTrials.gg
RecruitingNCT05795257ILLUMINA-1Updated Oct 22, 2026

Pulmonary Immune Cell-microbiome Interactions in ARDS

An observational study in ARDS, Human, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Hvidovre University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.
Updated Oct 22, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Respiratory Distress Syndrome with a site in Denmark — 3 open to participants now, 3 under way, 1 of them phase 3. Respiratory Distress Syndrome · Denmark.

Started
2023
the only one that year
Observational
5 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Hvidovre University Hospital

Among the 12 studies in Respiratory Distress Syndrome with a site in Denmark, this one is the only one that started in 2023, is one of 5 observational ones, and was the 12th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

3 of the 12 studies in Respiratory Distress Syndrome with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Respiratory Distress Syndrome with a site in Denmark, or all of them as a file.
02

Study summary

The overall aim is to compare the composition and spatial heterogeneity of the following in critically ill intensive care unit (ICU) patients: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome.

Main hypotheses:

  • The immune cell population in bronchoalveolar lavage fluid (BALF) from patients with ARDS is dominated by neutrocytes, while T cells are depleted, and show evidence of hyper-activation and exhaustion
  • T cell hyper-activation and exhaustion is specifically compartmentalised to the lungs, and much more pronounced in moderate-to-severe than none-to-mild ARDS
  • Cyto- and chemokines derived from pulmonary immune cells are higher in moderate-to-severe than none-to-mild ARDS with a greater release from lungs to the bloodstream, notably of IL-6 and IL-8.
  • The differences in T cell profile in BALF, notably the ratio between regulatory T cells and T helper 17 cells, will change with disease severity over time, and can be explained by the presence of tI-IFN antibodies and/or a low microbial diversity of the respiratory tract with low enrichment from the oral cavity.
Read the detailed description

Background Pulmonary hyperinflammation with neutrocyte and macrophage invasion and T cell depletion are common features of the acute respiratory distress syndrome (ARDS), but it remains to be elucidated whether the T cells in the lungs of patients with ARDS are hyperactivated and/or exhausted, and to which extent this contributes to neutrocyte invasion and thus lung tissue destruction. Furthermore, the pulmonary microbiome has shown a reduction in diversity and interactions in ARDS, which may be important for normal T cell function. At present, immune cell-microbiome interactions and their relation to disease severity and progression have not yet been studied in ARDS.

Overall design In 20 mechanically ventilated patients with none-to-mild and 20 with moderate-to-severe non-COVID-19 ARDS according to the Berlin definition an endotracheal aspirate and BAL fluid (BALF) from separate lung segments will be obtained. Furthermore, an oral and nasal swab and blood samples will be collected. This will be done within 72 hours after intubation, and again after 7-10 days if the patient is still intubated.

Patient's electronic health record The following is obtained after inclusion: diagnosis codes and medication (type and dosage, including vasopressors and sedatives), and smoking history (current/previous/never smoker; pack years); admission time; blood pressure, heart rhythm and heart rate, temperature, ventilator settings, supportive care (dialysis, ECMO), blood tests results at admission and on the study days (blood cell counts, coagulation parameters, renal, liver, and electrolyte panel; arterial and mixed venous blood gases); clinical scores at admission and on the study days (SAPS3, APACHE II, SOFA), death within 30 days

Blood sampling Arterial blood samples are drawn from the patient's invasive arterial catheter (inserted at ICU admission for clinical purposes: for continuous invasive blood pressure monitoring and repeated arterial blood gas collection) immediately before BALF collection.

Bronchoscopy with BALF collection This procedure is performed in a standardized fashion according to current clinical guidelines. Immediately prior to the procedure, an oral swab, nasal swab and an endotracheal aspirate (ETA) are obtained. FIO2 is then increased to 1.0, and the bronchoscopy procedure is performed using a disposable videoscope with an outer diameter of 5.0 mm). Three successive 50-ml aliquots of prewarmed (37°C) isotonic saline are instilled in the medial segment of the right middle lobe, aspirated immediately with low negative suction pressure (\< 100 cm H2O), and pooled into a sterile glass container on ice to obtain a BALF specimen.

Afterwards a mini-BAL is performed in the upper and lower lobe of the right lung with a single installation of 20 ml isotonic saline in each lobe with immediately aspiration into a sterile container.

Measurements The composition of the immune cell population, as well as the function and differentiation of various cell lines will be investigated by single-cell RNA sequencing (scRNA-seq) on selected immune cells from BALF, ETA, and blood, and this will be supplemented by bulk RNA sequencing with sample barcoding and multiplexing, giving a detailed expression pattern of all samples.

The composition microbiome in BALF, ETA, and oral swabs will be assessed by targeted amplicon sequencing of the hyper-variable regions 1 through 3 of the 16S subunit of ribosomal RNA gene for bacteria.

Statistical analyses will be performed using R statistical software version 4.1.1 (R Project for Statistical Computing) within RStudio statistical software version 1.4.1717 (RStudio), and p\<0.05 considered statistically significant. Inspection of normality and variance homogeneity will be done by creating qq-plots and histograms. The statistical inference tools SPIEC-EASI and HeatMaps will be used, and based on correlational analyses, principal component analyses, including non-hierarchal cluster analysis, will be applied to identify traits in the two groups.

03

Conditions studied

  • ARDS, Human
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Mechanically ventilated adult ICU patients at Hvidovre University Hospital

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria - moderate-to-severe ARDS
  • Admitted to the ICU at Hvidovre Hospital
  • Intubated within the past 72 hours
  • Moderate-to-severe ARDS according to the Berlin definition19
  • Age ≥ 18 years

Inclusion criteria - none-to-mild ARDS

  • Admitted to the ICU at Hvidovre Hospital
  • Intubated within the past 72 hours
  • None-to-mild ARDS according to the Berlin definition19
  • Age ≥ 18 years

Exclusion Criteria:

  • ARDS caused by COVID-19
  • Absolute for bronchoscopy
  • Untreated malignant arrhythmia
  • Documented or suspected intracranial hypertension (intracranial pressure ≥ > 15 mmHg)
  • One-lung ventilation
  • Severe coagulopathy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • None-mild ARDS

    Procedure: Bronchoalveolar lavage

  • Moderate-severe ARDS

    Procedure: Bronchoalveolar lavage

Interventions

  • ProcedureBronchoalveolar lavage

    Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung

06

What researchers measure

Primary outcomes

  1. Lung microbiome

    16S ribosomal RNA (rRNA) and 18S rRNA PCR for bacterial or fungal pathogen identification in bronchoalveolar lavage flui

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  2. Lymphocyte populations

    Cell populations and subpopulations evaluated by 10 colored flow cytometry (B cells, T cells, TCR subsets, Tregs/Th17, dendritic cells, myeloid cells and neutrophils) in bronchoalveolar lavage fluid and blood

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

Secondary outcomes

  1. Cell differential counts and cytomorphological analyses of BALF

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  2. Trans-compartmental fluxes

    (calculated from plasma- and urea-adjusted BAL)

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  3. Auto-antibodies against tI-IFNs in blood

    Measured in bronchoalveolarlavage fluid

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  4. White blood cells counts

    Total white blood cells, neutrocytes, lymphocytes, and monocytes in bronchoalveolar lavage fluid and blood

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  5. Cytokines

    Multiplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha, HMGB1)

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  6. Number and characterizations of respiratory pathogens

    Respiratory filmarray PCR for testing for number of pathogens

    Time frame: Day 0 (subsequent to study inclusion in the ICU)

  7. Number and characterizations of microorganisms

    Growth of pathogenic microorganisms in body fluids (e.g. urine, blood, bronchoalveolar lavage fluid) in microbiological assays

    Time frame: Up to 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Nov 2028, 68 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 68 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 3, 2023
StartActual
Mar 14, 2023
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Revised
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Eligibility Revised
    + 5 other changes: identifiers, verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05795257
Responsible party
Ronni R. Plovsing (Associate professor, Senior Consultant of ICU, Hvidovre University Hospital) — Principal investigator
First posted
Apr 3, 2023
Start date
Mar 14, 2023
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

MD, PhD, Ronni Plovsing
Contact
ronni.thermann.reitz.plovsing.01@regionh.dk
+45386220721
MD Katrine Schneider
Contact
katrine.schneider@regionh.dk
+4528118147
MD PhD Ronan berg
study chair · Biomedical Science of Health, University of Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion